Our findings affirm that isiBCL-2 molecules effectively stimulate the upregulation of IFN-β, CXCL10, and MHC-I levels in tumor cells via the RIG-I signaling pathway, promoting immune system activation and reversing the immunosuppressive tumor microenvironment. Here, RIGI is linked to neoplasm.